血细胞外囊中的KRAS突变等位基因频率动态:与局部胰腺腺癌生存的关联

相关实验视频

Updated: Jan 12, 2026

A Preclinical Murine Model of Hepatic Metastases

A Preclinical Murine Model of Hepatic Metastases

Published on: September 27, 2014

Asmita Chopra¹, Hong-Zhang He^2,3, Jadranka Milosevic^2,3

¹Department of Surgery, Division of Surgical Oncology Pittsburgh, Digestive Disorder Clinic, University of Pittsburgh, Pittsburgh, PA, USA.

Annals of surgical oncology

|November 4, 2025

概括

细胞外囊 (EVs) 中KRAS突变等位基因频率的增加预测胰腺癌患者的生存时间更短. 监测EV-KRAS MAF可以改善胰腺管腺癌 (PDAC) 治疗反应评估.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物标志物发现发现

背景情况:

胰腺管腺癌 (PDAC) 缺乏可靠的生物标志物,用于治疗监测和生存预测.
携带KRAS突变的细胞外囊 (EV) 显示出作为疾病特异性生物标志物的潜力.

研究的目的:

调查细胞外囊泡相关KRAS突变等位体频率 (EV-KRAS MAF) 动态作为接受新辅助治疗的PDAC患者的预测生物标志物的实用性.
为了将EV-KRAS MAF的变化与治疗反应,无病生存率 (DFS) 和整体生存率 (OS) 相关联.

主要方法:

血样本从44名PDAC患者在诊断时,后新辅助疗法 (NAT) 和手术后1个月收集.
分离了EV,并使用滴滴数字聚合酶链反应 (ddPCR) 来量化EV-KRAS突变.
根据时间EV-KRAS MAF变化对患者进行分类:没有检测到KRAS (ND),MAF下降 (DD),MAF增加 (ID).

主要成果:

在15.9%的患者中观察到EV-KRAS MAF (ID组) 的增加.
与ND和DD组相比,ID组的限制性无病平均存活时间 (rmDFS:9.8个月) 和整体存活时间 (rmOS:17.7个月) 显著较短.
在多变量分析中,增加EV-KRAS MAF独立预测较低的rmDFS (HR:6.14) 和rmOS (HR:6.95).

结论:

时间上升的EV-KRAS MAF是PDAC中减少DFS和OS的重要预测因素.
将EV-KRAS MAF动态与CA19-9等现有生物标志物的整合可以提高PDAC的治疗监测和生存预测.

关键词:

在KRAS突变中发生突变.腺癌是什么?腺癌是什么?腺癌是什么?细胞外囊泡细胞外囊泡突变等位基因的频率是多少胰腺癌是一种胰腺癌.生存结果的结果.

更多相关视频

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

相关概念视频

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...